The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend ...

With the FDA's approval of hereditary angioedema preventative treatment Andembry, CSL is ready to take on Takeda’s ...

Trump has threatened that pharmaceutical import tariffs could clock in at “25% or higher.” The President first floated the ...

Four U.S. senators have reintroduced a bipartisan bill focused on strengthening the pharmaceutical supply chain by ...

With Viatris taking home the biggest prize at this year’s Cannes Pharma Lions award and Biogen winning Gold, pharma is making ...

European marketers are feeling the squeeze, with a combination of shrinking budgets, rising targets and tightening compliance requirements piling on the pressure, ...

Amid a spate of high-profile investments in U.S. pharmaceutical production, two contract manufacturers are getting in on the ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

Founder and Global CEO of Doceree, returns with Season 2 of “The Next Marketing with HJ”—a one-of-a-kind, knowledge-packed ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...